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Introduction
This article is meant to disseminate recent scientific progress 
on Gilles de la Tourette Syndrome (TS).
Methods
We searched PubMed from time to time using the search strat-
egy “(“Tic Disorders”[MeSH] OR Tourette NOT Tourette[AU]) 
AND 2017[PDAT] NOT 1950:2016[PDAT]”. On 06 July 2018 
this search returned 212 citations. Colleagues also recom-
mended articles, and we attended medical conferences. We 
selected material to be discussed in this review subjectively, 
guided by our judgment of possible future impact on the field.
Results
A number of tic experts contributed to a review article on TS 
(Robertson et al., 2017).
Phenomenology and natural history
Schaefer et al. (2017) describe 16 people with TS who had 
experienced a clinical remission or marked improvement of 
more than 1 year’s duration, followed by symptomatic worsen-
ing as adults, leading them again to seek treatment. On average 
the “latent period” (the absence or substantial reduction in tics) 
had lasted 16 years. Seven of them had worse tics when return-
ing for care than they recalled as children. New substance use 
was reported as a trigger for exacerbation in 5 patients. This 
report strengthens evidence that even long-lasting symptomatic 
improvement in tic disorders (TDs) may not always be permanent, 
and that in fact the typical course of TS “is one of occasional 
recurrences of mild tics throughout adult life” (Black et al., 2016; 
Bruun & Budman, 1997); see also (Shapiro et al., 1988, p. 188; 
Stárková, 1990; Singer, 2006).
Regarding natural course and history, the fate of non-tic 
symptoms in TS has remained less well explored. A large Dan-
ish study reported follow-up data 6 years after enrolling 314 
children and teenagers with TS, assessing tics and comorbidities 
(mainly obsessive–compulsive disorder (OCD) and Attention-
Deficit/Hyperactivity Disorder (ADHD); N=226 at follow-up) 
(Groth et al., 2017). Most patients’ tics improved over time, but 
almost a quarter of those over age 16 still had severe tics, and 
only a sixth had no tics. The severity of OCD and ADHD declined 
significantly during adolescence, suggesting a shift towards 
so-called “pure” TS with age. Furthermore, the authors expected 
tic-related impairment to improve with an age-related decline 
in tic frequency and severity, but surprisingly the impairment 
score did not reflect the improvement in tics.
A report on 606 patients with a movement disorder starting 
in childhood produced an estimate for tic onset of 7.4 ± 3.8 
years with a mean delay to diagnosis of 9.9 ± 11 years 
(Bäumer et al., 2016).
Epidemiology. New and important findings this year involve 
the previously unappreciated risk of death in TDs. Meier 
et al. (2017) demonstrated that mortality rates are elevated in 
TS and other TDs, with or without comorbidities. In a very 
large epidemiological study, TDs in adults were associated with 
a four-fold higher risk of suicide, with the risk not explained by 
other psychiatric illness such as major depression (Fernández 
de la Cruz et al., 2017b). These researchers analyzed 7736 
TS/chronic tic disorder (CTD) cases in the Swedish National 
Patient Register over a 44-year period (1969–2013) and com-
pared them with control subjects from the general population. An 
increased risk of both suicide and attempted suicide was observed 
in TS/CTD patients, which was not solely dependent on psychi-
atric comorbidities. Tics that persisted beyond young adulthood 
significantly predicted completed suicide. Thus, TS/CTD is a 
serious medical condition that requires careful monitoring of 
suicidality. The same group also found a 7- to 10-fold higher 
risk of completed suicide in people with OCD, even after 
controlling for comorbid diagnoses (Fernández de la Cruz et al., 
2017a).
Martino et al. (2017c) review screening instruments and rating 
scales for TDs; see also (Augustine et al., 2017; Martino & 
Pringsheim, 2017).
Transient environmental effects on tic severity. A study of 45 
children with TS supported the typical antecedent–behavior– 
consequence behavioral psychology model (Eaton et al., 2017). 
Specifically, consequences of tics, “such as receiving accom-
modations or attention from others,” explained significantly 
more variance in tic severity than did the child’s level of separa-
tion anxiety, though the latter was also a significant factor. This 
study provides supportive evidence for the approach taken by 
“CBIT-Jr,” a behavior therapy designed for younger children 
with TS (Piacentini et al., 2015).
Other. Non-tic symptoms in TS are reviewed by Martino 
et al. (2017b). Lee et al. (2017) used Taiwan’s National Health 
Insurance Research Database to compare 1124 newly diagnosed 
TS patients to controls in a 1:3 match. Sleep disorders were 
twice as common in TS, and remained significantly higher 
in TS after accounting for anxiety disorders, which were the 
comorbid conditions associated with the highest risk. In a 
sample of 811 TS subjects recruited for a genetics study, hair 
pulling (3.8%) and skin picking (13.0%) disorders by DSM-5 
were surprisingly common (Greenberg et al., 2018).
Autism spectrum disorders (ASD) comprise an underexplored 
comorbidity of TD. There are few epidemiological studies on 
the subject but the prevalence of ASD in children with TDs is 
estimated at 20% (Khalifa & von Knorring, 2006). In a large 
study including patients with TD (n=535) and their family 
members (n=234), Darrow et al. (2017a) used the Social Respon-
siveness Scale Second Edition (SRS) to characterize ASD 
symptoms, and compared them to historical ASD samples. SRS 
scores in participants with TD were similar to those observed 
in other clinical samples but lower than in ASD samples. This 
is mostly but not entirely explained by elevations in the RRB 
(restricted interests and repetitive behaviors) subscale, which may 
be indicating tics rather than other stereotypic movements. The 
presence of OCD was associated with higher scores on the social 
cognition and RRB subscales. Complex tics and OCD symptoms 
(repetitive behaviors) can also be hard to discriminate from core 
ASD symptoms, especially those related to social communication.
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Etiology
A national database study found that parents of children with 
chronic tics had significantly higher rates of psychiatric illness: 
more than twice as high in mothers and 39% higher in fathers 
(Leivonen et al., 2017). The maternal risk, which included a 
range of psychopathology, was significantly higher than the pater-
nal risk, which comprised primarily OCD and anxiety disorders. 
Further work will be needed to clarify whether results reflect 
maternal-specific environmental risks, genetic risks, factors related 
to parental care-seeking, or (to a modest extent, given the typical 
ages of onset for various parental disorders identified) parental 
stress.
Genetics. A large mixed genetic sample yielded two heritable 
collections of symptoms that cross diagnostic boundaries, here 
named symmetry (including some other obsessions and com-
pulsions) and disinhibition (including complex verbal tics) 
(Darrow et al., 2017b). Whole exome sequencing from over 500 
trios identified a clear excess of likely gene-disrupting de novo 
mutations, and 4 risk genes that were altered by different 
mutations in multiple probands (Willsey et al., 2017). Another 
report described whole exome sequencing in a 3-generation 
family with TS, using induced pluripotent stem cells converted 
into neuronal cell types and assessing protein expression levels 
(Sun et al., 2018). The PNKD gene product was expressed 
at a lower rate in family members with TS or OCD.
Pathophysiology
Roger Albin wrote a very thoughtful review of TS as “a 
disorder of the social decision-making network” (Albin, 2018). 
Beste & Münchau (2018) describe tics in the context of the 
Theory of Event Coding, which describes the brain’s bidirec-
tional pairing of stimulus and movement. They note the salience 
of urges to most tic patients, and the fact that most tics are 
individually relatively normal movements, but occur repeat-
edly and out of context. Similarly, Shafer et al. (2017) focus on 
the strong connections between movement and sensory function 
to propose a theory that encompasses both the development 
of stereotypies as part of typical development and their persistence 
in maladaptive forms.
Animal models. A special issue on animal models of TS 
appeared in the Journal of Neuroscience Methods (Bortolato & di  
Giovanni, 2017). Articles reviewed gait and sensorimotor func-
tion in the D1CT-7 mouse model of TS (Fowler et al., 2017), 
stress mediating the timing of abnormal movements in animal 
models (Godar & Bortolato, 2017), and chemogenetic and 
optogenetic models (Burton, 2017). Deer mice have behavior 
that has been discussed as a natural model of OCD (Wolmarans 
et al., 2018).
Recently postnatal ablation of the TrkB receptor in cells 
expressing parvalbumin was shown to produce dramatic changes 
in cortex and cerebellum and “profound hyperactivity, stere-
otypies, motor deficits and learning/memory defects” (Xenos 
et al., 2017). This result may help explain why autopsies in 
TS show a lower number of parvalbumin-containing interneu-
rons in the striatum, but this model also produces much more 
substantial neuroanatomical changes than are seen in TS.
A gene identified in human OCD, slc1a1, which codes an 
excitatory amino acid transporter, was altered in mice to prevent 
its expression and function (Zike et al., 2017). The loss of this 
protein resulted in mice with reduced extracellular dopamine 
concentrations and reduced movement and stereotypic behavior 
after challenge with amphetamine or a dopamine D1 receptor 
agonist. Restoring the gene’s expression in the midbrain, but 
not in the striatum, partially rescued the exogenous dopamine-
induced stereotypies. This research is important for its direct 
links to human illness and its anatomical specificity, and lends 
additional support to testing dopamine D1 antagonists in TS 
(see Medication section, below).
New insights from computational modelling. Using the neu-
rophysiological data obtained from a TS animal model of 
pharmacological striatal disinhibition, Caligiore et al. (2017) 
proposed a computational model of the basal ganglia-cerebellar- 
thalamo-cortical system to address the mechanisms of motor 
tic generation in TS. Overall, the model suggested that inter-
play between dopaminergic signal and cortical activity triggered 
the occurrence of a tic and was able to predict the number of 
tics generated when striatal dopamine increases and when the 
cortex is externally stimulated. Maia & Conceição (2017) further 
discussed the role of tonic and phasic dopamine in tics learning 
and expression. Based on the existing literature of habit forma-
tion and reinforcement learning in TS, the authors proposed a 
model of tics as exaggerated and persistent motor habits rein-
forced by aberrant, increased phasic dopamine responses. 
According to this model, tonic dopamine release would serve to 
amplify the tendency to execute learned tics. The authors also pro-
posed the mechanism of antipsychotics’ action on tics: increased 
activity of indirect pathway due to antipsychotic administration 
could result in tic reduction, but at the same time potentially 
also could increase the propensity for reinforcing tics due to 
plasticity in the indirect pathway. In contrast, the authors also 
suggested that low-dose dopamine agonists could decrease both 
phasic and tonic dopamine and thus reduce both tic learning and 
tic expression. Both of these reports assume increasing tics with 
increasing dopamine concentrations, an assumption that seems to 
contradict observations that tics do not worsen with exogenous 
levodopa (Black & Mink, 2000; Gordon et al., 2013) nor improve 
with development of Parkinson disease (Kumar & Lang, 1997; 
Martinez-Torres et al., 2009; Shale et al., 1986). Furthermore, 
low-dose pergolide in children and adolescents with TS that 
reduced tic severity suppressed prolactin rather than increas-
ing it, consistent with overall enhancement of dopamine trans-
mission, at least in the hypothalamic-pituitary dopaminergic 
pathway (Gilbert et al., 2000a; Gilbert et al., 2000b).
Based largely on available functional anatomical studies, 
Conceição et al. (2017) also proposed a computational model 
of premonitory urges in TS. According to this model, premoni-
tory urges and in particular their termination, like termination 
of other aversive stimuli, might elicit positive prediction errors, 
supported by phasic dopamine release that would then rein-
force tics. The insula may play a central role in aversive feeling 
associated with premonitory urges and their learned negative 
value. The insula might send this information via direct or 
indirect projections to dopamine neurons, which might use it 
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for calculation of the positive prediction errors that occur with 
termination of the premonitory urge. In short, the authors 
provide a more detailed neurobiological explanation for the 
classic model that premonitory urges may strengthen tics 
through negative reinforcement.
Cognitive function and decision-making in TS. Morand-Beau-
lieu et al. (2017a) provide an updated and exhaustive review of 
neuropsychological aspects of TS (compare Eddy et al. (2009)). 
The review highlighted the slight alteration of social cognition 
as well as more frequent learning difficulties and disabili-
ties in children with TS. Recent data also seem to confirm the 
deficit in executive function in TS as indexed by poor per-
formance in continuous performance test and Stroop tests. 
Interestingly, using longitudinal evaluation of executive function 
in children with TS, Yaniv et al. (2018) showed that adults with 
TS showed response inhibition deficits, that tic reduction over 
time was significantly associated with development of response 
inhibition, and that former TS patients whose tics had remitted 
performed as well as, or on some tests better than, healthy 
control subjects. In contrast, the attentional and memory capacity 
seems to be impacted by comorbid symptoms more than TS per 
se. Sample size (n=122) or the healthy control group may explain 
different results obtained by Abramovitch et al. (2017), who 
studied treatment response in TS. They concluded that “the find-
ing that significant change in symptom severity of TS/CTD 
patients is not associated with impairment or change in inhibitory 
control regardless of treatment type suggests that inhibitory 
control [as measured by the tests selected] may not be a 
clinically relevant facet of these disorders in adults.” Given 
these contradictory results, Morand-Beaulieu et al. (2017b) 
review the puzzling question of inhibitory control in TS in a 
recent meta-analysis, and find larger inhibitory deficits in TS + 
ADHD patients, but this deficit was also present in “pure” TS. 
This deficit in TS was most prominent in verbal responses, was 
associated with tics severity as assessed with Yale Global Tic 
Severity Scale-Total Tics Score (YGTSS-TTS) and was larger in 
studies that included medicated TS patients.
Salvador et al. (2017) study decisional capacities in TS and 
specifically the ability to learn from the outcomes of alternative 
courses of action (known as counterfactual learning). Unmedi-
cated patients with TS showed normal performance on this task, 
whereas alteration was found in TS patients treated with the 
dopamine D2-like receptor (D2R) partial agonist aripiprazole, 
suggesting that modulating D2Rs may impair certain aspects 
of human reinforcement learning.
The Committee on Research of the American Neuropsychiatric 
Association published a systematic review on the neurobiology of 
the premonitory urge in TS (Cavanna et al., 2017). 
Electrophysiology. Brandt et al. (2017) reported on enhanced 
multi-component behavior in TS, which was also reflected in 
a smaller P3 event-related potential measured by EEG and 
potentially related to chronic tic control in these patients. An 
EEG study during simulated driving found that “mind wander-
ing” may be quantifiable using EEG measures of alpha power 
and the P3a component of an auditory event-related potential 
(Baldwin et al., 2017). Since mind wandering is a defining 
feature of ADD, in addition to being ubiquitous during repeti-
tive tasks, these measures may prove useful in studying ADHD 
phenomenology in TDs.
Neuroimaging studies. Polyanska & colleagues (2017) provide a 
meta-analysis of task-based neuroimaging reports in TS. Adults 
with TS show some impairment in lateralized sequential finger 
tapping movements, and this impairment was compared to frac-
tional anisotropy of white matter tracts connecting primary 
motor cortex (M1) to M1 and supplementary motor area 
(SMA) to SMA (Martino et al., 2017a).
Previous in vivo MRI studies of basal ganglia volume and shape 
in TS have produced differing results (reviewed in Greene 
et al. (2017)). A study of 47 children age 8-12 with TS, and 
controls with or without ADHD, found no significant group 
differences (Forde et al., 2017).
A PET study of the microglial activating marker TSPO in OCD 
found elevated TSPO concentrations in dorsal caudate, orbit-
ofrontal cortex, thalamus, ventral striatum, dorsal putamen, 
and anterior cingulate cortex (Attwells et al., 2017). Concen-
trations in patients were about 1/3 higher than in controls. 
This report implicates low-level brain inflammation in the 
pathophysiology of OCD.
Clinical and neuropsychological studies. A study using the 
alternating serial reaction time task found no impairment of pro-
cedural learning in TS or ADHD (Takács et al., 2017). This result 
is surprising, given that habit learning on a “weather prediction” 
task is slower in TS (Kéri et al., 2002; Marsh et al., 2004), 
but may indicate that the two tasks engage different learning 
systems, a conclusion supported by the generally normal 
cognitive function in TS.
Münchau and colleagues extended their previous work on echo-
praxia (imitation) to children with TS (Brandt et al., 2017). 
Participants were asked to lift either their index or pinky 
finger when prompted by an auditory tone; simultaneously 
they were shown a compatible or incompatible visual stimulus. 
Children with TS were slower overall but thereby gained less 
interference from the incompatible stimulus. The authors 
conclude that these results suggest that children with TS may 
employ “different or additional inhibition strategies” than 
children without tics. Again, on this task children with TS show 
superior, not deficient, action inhibition.
Treatment
Ganos et al. (2017) review treatments for TDs in children.
Psychological interventions. Houghton et al. (2017) analyzed 
their existing data to test the longstanding theory that habitu-
ation to premonitory urges during adequate periods of tic 
suppression is the mechanism by which behavior therapies for 
tic disorders exerted their beneficial effects. In two previous 
randomized trials, 126 children and adolescents and 122 adults 
with TS or a persistent TD had been assigned to Comprehen-
sive Behavioral Intervention for Tics (CBIT) or to education 
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and supportive therapy. The prediction was that urge sever-
ity would decrease in CBIT responders. Surprisingly, however, 
children showed no significant reduction in premonitory urges 
with treatment, even though CBIT was quite effective in the child 
study, and declines in urges in adults had no association 
with clinical improvement or group assignment. The authors 
conclude that habituation cannot be the underlying process 
by which CBIT exerts its beneficial effects. This important result 
warrants further study.
Another report from the same data set examined what clinical 
features at baseline predicted improvement in tics during 
treatment (Sukhodolsky et al., 2017). Importantly, those treated 
with CBIT improved regardless of medication status, while in 
the control (supportive therapy) group, tics improved only in 
those taking medication for tics. Also importantly for the under-
standing of behavior therapy in TS and patient selection, other 
psychiatric symptoms, age, sex, family functioning, and expec-
tation of improvement had no significant effects on benefit from 
therapy. And contrary to some opinions, patients with worse tic 
severity had significantly better improvement in tics with CBIT. 
Anxiety disorders and, surprisingly, more severe premonitory 
urges predicted less improvement.
O’Connor and colleagues published a book describing their com-
bined psychotherapeutic approach to tics (O’Connor et al., 2017).
Several groups reported efforts to increase dissemination and 
use of behavior therapy for tics. An internet-based, thera-
pist-guided behavior therapy for tics is being studied in the 
BiP-TIC project (Karlsson, 2016). The TicHelper.com inter-
net-based CBIT program went live in late 2017 and received a 
positive review (Conelea & Wellen, 2017).
Medication. A group of international experts provided a status 
report and recommendations for using brain imaging for the 
rational development of novel psychopharmacological interven-
tions (Suhara et al., 2017). As an example, a fascinating study in 
pediatric ADHD showed that fMRI response to a cognitive task 
(Go/No-Go) strongly predicted better clinical response to methyl-
phenidate than to atomoxetine (Schulz et al., 2017). As the authors 
conclude, “These data do not yet translate directly to the clini-
cal setting, but the approach is potentially important for inform-
ing future research and illustrates that it may be possible to 
predict differential treatment response using a biomarker-driven 
approach.”
Initial results from the first randomized, controlled trial (RCT) 
with a dopamine D1 receptor antagonist in pediatric TS were 
released by the sponsor in January, 2017 (Chipkin, 2017). 
These new results supported the positive results from a pilot 
study in adults with TS (Gilbert et al., 2014), and suggest 
a novel treatment mechanism for tics.
In April, the US FDA approved the presynaptic dopamine deplet-
ing agent valbenazine (Ingrezza®) for treatment of tardive 
dyskinesia (Neurocrine Biosciences, Inc. 2017b). TS is a likely 
off-label use for the drug, as the company has been conduct-
ing studies in children and adults with TS (ClinicalTrials.gov). 
The FDA designated valbenazine an orphan drug for pediatric 
patients with TS (Neurocrine Biosciences, Inc. 2017a). Another 
VMAT2 inhibitor, tetrabenazine, has been used for some time 
in the treatment of TS (Marsden, 1973; Sweet et al., 1974; 
Jankovic, 2016). A related compound, deutetrabenazine (Paton, 
2017), showed initial positive results in TS (Jankovic et al., 2016), 
and the FDA approved it for treatment of tardive dyskinesia in 
August (Business Wire, 2017).
Aripiprazole has become a drug of choice in treating tics and 
comorbidities in TS over the past decade. However, large 
scale trials have been missing. Moreover, aripiprazole is not 
marketed for children and adolescents in many countries, 
regardless of the indication. Sallee et al. (2017) report on a 
phase 3, randomized, double-blind, placebo-controlled trial in 
133 pediatric patients randomized in a 1:1:1 ratio to low-dose 
aripiprazole (5 mg/day if <50 kg; 10 mg/day if ≥50 kg), high-
dose aripiprazole (10 mg/day if <50 kg; 20 mg/day if ≥50 kg), 
or placebo for 8 weeks. The primary efficacy endpoint was 
mean change from baseline to week 8 in the YGTSS-TTS. The 
Clinical Global Impression-Tourette’s Syndrome improvement 
score was also evaluated. High-dose aripiprazole was more 
effective than low-dose aripiprazole, and both were superior 
to placebo. Importantly, tolerance was overall good and no 
serious adverse events or deaths occurred, indicating that oral 
aripiprazole is a safe and effective treatment for tics in children 
and adolescents. These results provide important reassurance to 
clinicians who have been using aripiprazole for TS for years now. 
The placebo response rate (for the Clinical Global Impression 
scale), though half the response rate in the active treatment 
groups, was nevertheless surprisingly high (38%).
A small (N=34) RCT of guanfacine showed no meaningful 
difference in effects on tic ratings or clinical impressions of 
improvement between the drug and placebo groups (Murphy 
et al., 2017). This result is important and surprising, given that 
adrenergic α2 agonists have been seen as first-line treatment for 
TS, especially in TS patients with ADHD (Hollis et al., 2016). 
Both these studies show how important RCTs are to clinical 
care in TS. Speaking of RCTs and guanfacine, a press release 
reported that extended-release guanfacine showed superiority 
to placebo in adults with ADHD (discussed here). The impor-
tance of this report comes primarily from the fact that data on 
ADHD treatments are scarcer in adults than in children.
Cannabinoids for TS are increasingly being studied; a brief 
summary of some of this work appears in Black (2017).
Neurosurgery. A fascinating study demonstrated in mice that 
interfering electrical “beats” (similar to the beats one hears when 
tuning one instrument to another) can be used to steer neuron 
activation to focal sites in the brain without surgical electrode 
implantation (Grossman et al., 2017). Much work remains to be 
done to demonstrate feasibility, safety and efficacy in humans, 
but this approach potentially could lead to noninvasive, focal brain 
stimulation.
Welter et al. (2017) performed a randomized, double-blind, 
controlled trial of deep brain stimulation (DBS) of the posterior 
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and anterior internal globus pallidus for severe TS. The design 
was very similar to that reported previously by Kefalopoulou 
et al. (2015), and so were the results. The primary endpoint was 
the difference in YGTSS score between the beginning and end 
of the 3 month double-blind period. No significant differences 
between groups were noted in YGTSS score change between 
the beginning and the end of the 3 month double-blind period, 
despite a slight improvement in the stimulated condition. How-
ever, after the end of the open stimulation period and further 
parameter adjustment, results become significant compared to 
baseline. Also, when turning the stimulators off in a blinded 
fashion, YGTSS scores increased again to reach near baseline 
levels. Overall, this study is most important in terms of optimal 
study design. The stimulator programming period preceding the 
blinded phases was likely too short and the parameters subop-
timal (a choice intended to reduce unblinding). Future studies 
will need to consider these results carefully.
A London center reported an analysis of GPi DBS data, 
looking for the “sweet spot” for DBS for tic improvement 
(Akbarian-Tefaghi et al., 2017). They report that “a region within 
the ventral limbic GPi, specifically on the medial medullary lam-
ina in the pallidum at the level of the AC-PC, was significantly 
associated with improved tics but not mood or OCB outcome.” 
Two patients with DBS to the fields of Forel experienced a good 
outcome (Neudorfer et al., 2017).
TS patients undergoing DBS, independent of the surgical 
target, usually require high stimulation parameters, leading 
to short (2–3 years) battery life, meaning frequent and costly 
battery replacements. Michael Okun and colleagues showed proof 
of the principle that triggered rather than continuous DBS may 
be helpful (Molina et al., 2017). In a single patient with medi-
cally refractory TS, a spectral feature in the 5- to 15-Hz band 
was used as the control signal from bilateral leads in the 
centromedian-parafascicular (Cm-Pf) region of the thalamus. 
Significant tic improvement compared to baseline was observed 
12 months after the procedure, similar to that obtained with 
continuous DBS, and resulted in a 63% improvement in the 
neurostimulator’s projected mean battery life. These so called 
closed-loop systems are gaining traction in various CNS 
diseases where DBS is applied, and this case report paves 
the way in TS.
A report from the DBS group in the Netherlands called 
attention to side effects over the course of treatment in TS 
patients with thalamic DBS (Smeets et al., 2018). A subthalamic 
nucleus (STN) DBS study in OCD reminds us that DBS can 
cause side effects; STN stimulation at higher voltages caused 
chorea-ballismus (Mulders et al., 2017).
Tics, family and society
Quality of life is lower in parents of children with TS and 
is more related to factors other than tic severity (Jalenques 
et al., 2017). Stewart et al. (2015) previously reported similar 
results. These studies emphasize the need to assess and treat 
symptoms other than tics in TS patients, and to care for the whole 
patient.
Conclusions
2017 has again seen a rise in publications on TS, reflecting the 
increased interest this field receives, both from clinicians and 
researchers devoted to this disorder but also from adjoining fields, 
given the substantial psychopathology associated with TDs.
One important question raised is the natural course of TS 
and the rate of (non-)remission. Recent data suggest that the 
optimistic outlook prevalent with regard to tic severity when 
gliding from adolescence into adulthood might not be com-
pletely justified. Here, large longitudinal studies are warranted, 
and also to better understand the prognostic factors associated 
with tic remission or persistence. The fate of comorbidities also 
needs to be better understood, even though data have begun to 
emerge. We also still face important delays in the diagnosis of 
TS, and we need to deal with the recently demonstrated increased 
suicide risk in this condition, which underlines that TDs are far 
from benign.
Of note, there is a rise in computational models of TS, which 
provide important leads to understanding its pathophysiology 
and will likely fuel more targeted treatment approaches for tics. 
In the therapy field, 2017 has mainly seen studies centered on 
well-known pharmacological targets such as the dopaminergic 
system; however, new antidopaminergic medications were 
studied or came to the market in 2017, and increasing data 
supports existing off-label prescription practices. Behavioral 
therapy continues to emerge as a main pillar of tic treatment, 
with an improved understanding of its mechanisms and response 
factors. In the surgical field, deep brain stimulation for severe 
TS cases continues to draw interest; in particular, target choice, 
length of stimulator programming for optimal outcome, and 
closed-loop systems are under active investigation.
Overall, the field is active and burgeoning. Breakthroughs are 
to be expected in the upcoming years, especially with regard 
to large-scale efforts in the field.
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